Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
4d Pharma Plc LSE:DDDD London Ordinary Share GB00BJL5BR07 ORD 0.25P
  Price Change % Change Share Price Shares Traded Last Trade
  -1.40 -1.34% 103.40 862,356 16:35:22
Bid Price Offer Price High Price Low Price Open Price
103.60 104.20 106.00 100.80 106.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.53 -30.35 -22.80 186
Last Trade Time Trade Type Trade Size Trade Price Currency
17:08:13 O 68,120 103.40 GBX

4d Pharma (DDDD) Latest News

More 4d Pharma News
4d Pharma Investors    4d Pharma Takeover Rumours

4d Pharma (DDDD) Discussions and Chat

4d Pharma Forums and Chat

Date Time Title Posts
15/6/202105:144D Pharma 2018 - from Ј2 back up to Ј10+22,772
10/5/202119:064d Pharma588
17/11/202020:53DDDD : 4D and the Microbiome sector-
09/11/202007:424D Pharma - Best Risk Reward Play on AIM12
08/3/202021:164D Pharma (DDDD) One to Watch 8

Add a New Thread

4d Pharma (DDDD) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2021-06-14 16:08:13103.4068,12070,436.08O
2021-06-14 16:02:58104.183,5363,683.80O
2021-06-14 15:35:22103.4017,40817,999.87UT
2021-06-14 15:29:58103.60680704.48AT
2021-06-14 15:29:58103.60687711.73AT
View all 4d Pharma trades in real-time

4d Pharma (DDDD) Top Chat Posts

DateSubject
14/6/2021
09:20
4d Pharma Daily Update: 4d Pharma Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker DDDD. The last closing price for 4d Pharma was 104.80p.
4d Pharma Plc has a 4 week average price of 88p and a 12 week average price of 88p.
The 1 year high share price is 183p while the 1 year low share price is currently 35.60p.
There are currently 180,299,728 shares in issue and the average daily traded volume is 2,010,891 shares. The market capitalisation of 4d Pharma Plc is £186,429,918.75.
11/6/2021
17:57
thepaddedcell: I read all the posts on here, the good, the bad and the ugly. It doesn't take a genius to work out those who talk BS. At the moment there appears to be plenty of sore losers who didn't buy early last year when the share price was under 50p. They are here now trying to discredit the company in a vain attempt to drive the price down. Anyone who takes on board their blatant whinging and sells shouldn't be investing ! I don't think people on here take any notice. The wining whingers are just wasting their breath and talking to themselves for the most part ! You can make your own minds up who I'm talking about.
11/6/2021
09:26
devonlad: There is a document in which the directors of LBPS, formerly Longevity, put forward the takeover of the spac to their shareholders. Within that document, the board recommended the offer of a takeover from DDDD and part of their reasoning was the disparity of mcap between DDDD and the peers in the USA. If memory serves me correctly, they valued DDDD at that time, so around January, at £3 a share. The only thing that has really changed since then and now I think is the improvement in the Blautix data. Thus, the disparity still exists. However, if the read out due soon in June or July I believe for MRX0518 with Keytruda is good, that disparity will widen at the current share price. So those looking for £1.10 ot £1.30 a share are really missing the point here. DDDD is now listed on the Nasdaq, but that disparity still exists and a good read out should go some way to attracting the more knowledgable investors that the Nasdaq listing was designed, and thus far failed, to achieve. Each to their own, short trem traders are welcome, they improve liquidity but at some point, that disparity will clear, either DDDD is undervalued or the peers are over valued. Given that DDDD has something like ten times the number of patents granted and pending in comparison with Seres, you could well argue that it should be worth more than £3 a share. However, this is new science, it is still unproven to a certain extent, that is the risk you are taking.
08/6/2021
11:39
pistolwhip: It's the no.1 resource we all have to get a decent, informed handle on the company Reb_Ban. But it's my guess only a handful of those posting here have read it in its entirety. The question is, do you let the current share price guide you as to the potential value at 4D, or do you review the programs, space and data as presented in docs such as that prospectus...and then make a call. Personally, I am thoroughly 'dissuaded' and unconvinced by the current weakness in the share price and have continued to see it as a buying opportunity. Now I may well be wrong.....and the current weakness may turn out to be a sound indicator of low value and systemic problems, but my gut says the value of the parts at 4D and what has already been discovered and achieved is well advanced of the current share price The market at large currently disagrees with me.......but I have made my call.
05/6/2021
19:45
daveweld2: Big few months approaching with news release, seems pretty clear that 4d peers have recognition in micro biome space with valuations to suit, will be interesting to see if 4d can produce the goods (data) again !! and move the share price forward, bod certainly believe that will be the case, have seen this type of share price action several times with other companies sinking well below raise price, many regroup and push ahead once the weak have departed, nature of the game.....I use the near constant negativity of some as my drive, hence rarely post but listen and learn, Many bb's (not just this one) globally use negative tactics to shake, shake, and shake again, remember when syn was at 80p (after falling from 200+) bb "experts" stated was going back to 30p's, a concerted effort of negativity took over bb's, 4 weeks later was 160p....It's tactics, the stock market is a cesspit, you need a thick skin and patience,Some are suggesting share price could fall below support,I haven't a crystal ball, maybe it will, maybe it will hit stigs 1000p target by end of year, he hasn't a crystal ball either, if unsure, read as many do the sec Nasdaq filing, looks pretty compelling story to me....and laugh at the bs posts, ask yourself why would people post constant negativity....?It's a time honoured practice... without the honour bit !!!
01/6/2021
10:09
pistolwhip: My view is that the potential of this company has only grown over the past 12 months or so. The share price performance is a surprise and yes a disappointment but as the price drifts I am always much closer to adding than selling - any. Personally I remain fully invested and with growing funds on the sidelines I choose to see an increasing opportunity. From a sector, pipeline and clinical perspective, on information available (both company specific and non-company specific), 4D remains a compelling company in a compelling space. Just my view.....albeit not reflected in the price action at present, granted.
28/5/2021
11:44
the donald: We don't know the milestone payment criteria. I'm guessing they would be geared towards near commercialisation rather than 'their efforts'. As others have said here, Mrx0518 part B readouts should have the desired effect on the share price. For the doubters, Alex and Duncan are on modest salaries yet they subscribed for another £650,000 shares each at 110p. They bought placing shares last year at nearly a quarter that price. That tells me all I need to know. They know the results to date on Mrx 0518, we don't.....yet.
21/5/2021
14:37
tyler90: AIMHO but if there was to be price moving news in the presentation the share price would probably have started to move by now...these things have a habit of leaking. In fact, the drop in share price in recent weeks is an indication that it is not going to be as good as people are hoping for. I hope I am wrong since holding but not expecting too much :-(
11/5/2021
11:59
pistolwhip: Not really wigwammer. I would sell if I didn't rate the prospects here, or if something very fundamental had changed. But on the info I'm looking at, the original reasons to INVEST, remain. The share price has changed. But I don't see that the story has? The ironic thing is, if this had been edging higher and higher over the past few weeks, without news, people would be buying in and the share price would be self fulfilling in the opposite sense. And this board would be awash with optimism. But that optimism would not necessarily be well-founded, just as the present gloom might not be well-founded. Unless there is something bad looming, I tend to buy weakness. Sell volumes in recent times have been modest so..... You makes your choice and you takes your chance...
27/4/2021
07:38
shrewdmole: My take on price/II involvement is this. There wasn’t enough stock after the Nasdaq listing for the nterested II to accumulate in any volume hence why the rns about swapping stock over for uk holders. What we have seen last couple of weeks is the share price being managed so stock can be moved from aim to Nasdaq at around or slightly above placing price. Once this has been completed I expect news to start flowing and the price to adjust accordingly. I’m taking advantage of the current managing of the price before the US does get involved as the volume is there for them to do so.
16/4/2021
07:55
pistolwhip: 4d Pharma PLC Directors' Subscription for new Ordinary Shares 16/04/2021 7:00am UK Regulatory (RNS & others) 4d Pharma (LSE:DDDD) Intraday Stock Chart Friday 16 April 2021 Click Here for more 4d Pharma Charts. TIDMDDDD RNS Number : 6612V 4d Pharma PLC 16 April 2021 4D pharma plc Directors' Subscription for new Ordinary Shares Leeds, UK - 16 April 2021 - 4D pharma plc (AIM: DDDD; Nasdaq: LBPS) ("4D" or the "Company"), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, announces that further to the announcement released on 22 March 2021 which detailed the Company's private placement to raise approximately $25.03 million (GBP18.01 million) (the "Fundraising"), Duncan Peyton (Chief Executive Officer) and Alex Stevenson (Chief Scientific Officer) have agreed to subscribe for, in aggregate, approximately $2.0 million (GBP1.44 million) of new ordinary shares of GBP0.0025 each (the "Subscription Shares") at GBP1.10 ($1.52) per share (the "Subscription Price"). Admission and dealings Application has been made to the London Stock Exchange plc for admission of the Subscription Shares to trading on AIM ("Admission") and Admission is expected occur at 8.00 a.m. on 22 April 2021. The Subscription Shares will, when issued, be credited as fully paid and will rank pari passu in all respects with the existing ordinary shares of the Company, including the right to receive all dividends or other distributions made, paid or declared in respect of such shares after the date of issue of the new ordinary shares. Related party transaction The details of the Subscription Shares are set out below: Director Existing Ordinary Ordinary Percentage Shares Subscription Consideration Shares of Enlarged currently Shares subscribed per Subscription held Share Capital held for Share on Admission on Admission Duncan Peyton 8,855,931(1) 658,840 GBP1.10 9,514,771 5.28% Alex Stevenson 8,699,624(2) 658,840 GBP1.10 9,358,464 5.19% (1) In the circular dated 26 February 2021 this was disclosed as 8,855,059 (2) In the circular dated 26 February 2021 this was disclosed as 8,698,961 The Directors' participation in the Fundraising, as set out above, constitutes a related party transaction pursuant to Rule 13 of the AIM Rules for Companies. The Independent Directors, being the Directors not participating in the Subscription, having consulted with N+1 Singer, the Company's nominated adviser, consider that the individual, respective subscriptions by Duncan Peyton and Alex Stevenson in the Fundraising are fair and reasonable insofar as shareholders are concerned. Total Voting Rights Following Admission, 4D's enlarged issued share capital will comprise 180,299,728 ordinary shares. The total number of voting rights in the Company will be 180,299,728. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority. Contact Information: 4D pharma Investor Relations: ir@4dpharmaplc.com N+1 Singer - Nominated Adviser and Joint Broker +44 (0)20 7496 3000 Philip Davies / Iqra Amin / James Fischer (Corporate Finance) Tom Salvesen (Corporate Broking) Bryan Garnier & Co. Limited - Joint Broker +44 (0)20 7332 2500 Dominic Wilson / Phil Walker Stern Investor Relations, Inc. +1-212-362-1200 Julie Seidel Julie.seidel@sternir.com Image Box Communications +44 (0)20 8943 4685 Neil Hunter / Michelle Boxall neil@ibcomms.agency / michelle@ibcomms.agency Forward-Looking Statements This announcement contains "forward-looking statements." All statements other than statements of historical fact contained in this announcement, including without limitation statements regarding the admission and trading of Ordinary Shares, are forward-looking statements within the meaning of Section 27A of the United States Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the United States Securities Exchange Act of 1934, as amended (the "Exchange Act"). Forward-looking statements are often identified by the words "believe," "expect," "anticipate," "plan," "intend," "foresee," "should," "would," "could," "may," "estimate," "outlook" and similar expressions, including the negative thereof. The absence of these words, however, does not mean that the statements are not forward-looking. These forward-looking statements are based on the Company's current expectations, beliefs and assumptions concerning future developments and business conditions and their potential effect on the Company. While management believes that these forward-looking statements are reasonable as and when made, there can be no assurance that future developments affecting the Company will be those that it anticipates. All of the Company's forward-looking statements involve known and unknown risks and uncertainties, some of which are significant or beyond its control, and assumptions that could cause actual results to differ materially from the Company's historical experience and its present expectations or projections. The foregoing factors and the other risks and uncertainties that could cause actual results to differ materially include potential delays in the process of Admission. The Company wishes to caution you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly update or revise any of its forward-looking statements after the date they are made, whether as a result of new information, future events or otherwise, except to the extent required by law. 1 Details of the person discharging managerial responsibilities / person closely associated a) Name Duncan Peyton -------------------------- ------------------------------------------------- 2 Reason for the notification ----------------------------------------------------------------------------- a) Position/status Chief Executive Officer -------------------------- ------------------------------------------------- b) Initial notification Initial /Amendment -------------------------- ------------------------------------------------- 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor ----------------------------------------------------------------------------- a) Name 4D Pharma plc -------------------------- ------------------------------------------------- b) LEI 213800O49VYSXWE2ZD52 -------------------------- ------------------------------------------------- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ----------------------------------------------------------------------------- a) Description of the Ordinary shares of 0.25 pence each financial instrument, type of instrument GB00BJL5BR07 (Ordinary Shares) Identification code -------------------------- ------------------------------------------------- b) Nature of the transaction Purchase of Ordinary Shares pursuant to the Fundraising -------------------------- ------------------------------------------------- c) Price(s) and volume(s) Price Volume -------------------------- ----------------------- ------------------------ 110 pence per Ordinary 658,840 Ordinary Shares Share -------------------------- ----------------------- ------------------------ d) Aggregated information N/A - Aggregated volume - Price -------------------------- ------------------------------------------------- e) Date of the transaction 15 April 2021 -------------------------- ------------------------------------------------- f) Place of the transaction Off market transaction -------------------------- ------------------------------------------------- 1 Details of the person discharging managerial responsibilities / person closely associated a) Name Alex Stevenson -------------------------- ------------------------------------------------- 2 Reason for the notification ----------------------------------------------------------------------------- a) Position/status Chief Scientific Officer -------------------------- ------------------------------------------------- b) Initial notification Initial /Amendment -------------------------- ------------------------------------------------- 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor ----------------------------------------------------------------------------- a) Name 4D Pharma plc -------------------------- ------------------------------------------------- b) LEI 213800O49VYSXWE2ZD52 -------------------------- ------------------------------------------------- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ----------------------------------------------------------------------------- a) Description of the Ordinary shares of 0.25 pence each financial instrument, type of instrument GB00BJL5BR07 (Ordinary Shares) Identification code -------------------------- ------------------------------------------------- b) Nature of the transaction Purchase of Ordinary Shares pursuant to the Fundraising -------------------------- ------------------------------------------------- c) Price(s) and volume(s) Price Volume -------------------------- ----------------------- ------------------------ 110 pence per Ordinary 658,840 Ordinary Shares Share -------------------------- ----------------------- ------------------------ d) Aggregated information N/A - Aggregated volume - Price -------------------------- ------------------------------------------------- e) Date of the transaction 15 April 2021 -------------------------- ------------------------------------------------- f) Place of the transaction Off market transaction -------------------------- -------------------------------------------------
4d Pharma share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
DDDD
4d Pharma
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210615 04:45:05